Long‐Term Outcomes and Prognosis Factors in Patients With Idiopathic Inflammatory Myopathies Based on Myositis‐Specific Autoantibodies: A Single Cohort Study
Authors' conclusion
Despite favorable overall survival in patients with IIM, the anti-MDA-5-positive subgroup had the highest mortality rate among all MSA subgroups, highlighting the distinctive prognosis for patients with different MSAs. RP-ILD and malignancy are the most common causes of death in IIM patients.
Study context
- Population
- Patients with IIM stratified by myositis-specific antibody (MSA)
- Participants
- 628 patients
- Exposure
- Survival and prognostic factors by MSA subgroup
- Outcome
- Long-term survival
- Follow-up
- 1, 5 and 10 years
Methodological detailssingle cohort, Kaplan-Meier survival analysis, univariate and multivariate Cox regression
- Single cohort
- Kaplan-Meier survival analysis
- Univariate and multivariate Cox regression
Main finding
As reported in the abstract
Cumulative survival, IIM overall
- 1-year survival, overall
- 91.4%
- 5-year survival, overall
- 82.8%
- 10-year survival, overall
- 75.6%
- Survival differed significantly across MSA subsets
- P < 0.001
- 1-year survival, anti-MDA-5-positive (lowest of all subgroups)
- 79.5%
- 10-year survival, anti-MDA-5-positive (lowest of all subgroups)
- 58.5%
- 10-year survival, anti-signal recognition particle (anti-SRP)-positive (highest)
- 96.4%
Observational data: associations, not effects.
Further findings
Independent prognostic factors for long-term prognosis, IIM overall (multivariate Cox)
- Rapidly progressive interstitial lung disease (RP-ILD), HR (P < 0.01)
- 17.47
- Malignancy, HR (P < 0.01)
- 20.36
- Elevated serum ferritin, HR (P < 0.01)
- 9.15
- Disease duration (protective), HR (P = 0.003)
- 0.27
Independent risk factors for death by MSA subgroup
- RP-ILD in anti-MDA-5-positive, HR (P = 0.017)
- 3.4
- Malignancy in anti-aminoacyl-tRNA synthetase antibody-positive, HR (P < 0.001)
- 46.69
- Malignancy in anti-TIF1γ-positive, HR (P < 0.001)
- 6.65
- Malignancy in MSA-negative, HR (P < 0.001)
- 4.48
- RP-ILD in MSA-negative, HR (P < 0.001)
- 72.28
Original publication
Long‐Term Outcomes and Prognosis Factors in Patients With Idiopathic Inflammatory Myopathies Based on Myositis‐Specific Autoantibodies: A Single Cohort Study. Arthritis Care Res (Hoboken). Published 11 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →